Maddox-Rooper Taylor R, Sklioutouskaya-Lopez Kristiana, Sturgill Trenton, Fresch Caroline, Clements Charles W, Lamichhane Rajan, Egleton Richard, Davies Todd H
Department of Family and Community Health, Joan C Edwards School of Medicine at Marshall University, Huntington, West Virginia, USA.
Recovery Point of West Virginia, Huntington, West Virginia, USA.
Alcohol Clin Exp Res. 2022 Oct;46(10):1865-1874. doi: 10.1111/acer.14913. Epub 2022 Aug 25.
Connecting patients to treatment for a substance use disorder (SUD) that satisfies their needs is often complicated by confounding factors. A reliable measurement of patients' underlying stress level may be helpful because it often reflects many of the same confounders as their SUD. Whereas cortisol levels reflect physiological responses to stress, patients' cortisol levels during recovery from an SUD may serve as biomarkers for stressors that result in poor treatment outcomes, including early discontinuation of treatment. However, further exploration of the relationship between patients' cortisol levels and their treatment outcomes is needed for this approach to be clinically useful.
We enrolled participants from an abstinence-based, male-only, residential alcohol and drug recovery program to examine the relationship between salivary cortisol, stress exposure, ACEs, and treatment retention.
Participants who remained in the program <90 days had significantly higher initial cortisol levels than those who remained ≥90 days (0.62 ± 0.074 μg/dl vs. 0.36 ± 0.037 μg/dl). Kaplan-Meier curves differed significantly when we grouped participants according to whether their cortisol level was below or above the overall average of 0.49 ± 0.044 μg/dl, with the median numbers of days before discontinuing being 110 and 60, respectively. A Cox proportional hazards model indicated that elevated salivary cortisol (with increases in μg/dl), marital/relationship status, and adverse childhood experiences (ACEs) score correlated significantly with hazards of discontinuing the program (hazard ratios for the three factors were 3.49, 2.39, and 1.50, respectively).
Cortisol level may predict, at least partially, SUD treatment program retention regardless of individuals' numerous confounding factors or the substance used. If this approach is validated, it could enable providers to consider patients' cortisol levels at the time of admission to treatment to facilitate their retention in treatment and thereby enhance their recovery.
将患有物质使用障碍(SUD)的患者与满足其需求的治疗联系起来,往往会因混杂因素而变得复杂。可靠地测量患者潜在的压力水平可能会有所帮助,因为它通常反映出许多与他们的物质使用障碍相同的混杂因素。虽然皮质醇水平反映了对压力的生理反应,但患者在从物质使用障碍中恢复期间的皮质醇水平可能作为导致治疗效果不佳(包括提前终止治疗)的压力源的生物标志物。然而,要使这种方法在临床上有用,还需要进一步探索患者皮质醇水平与其治疗效果之间的关系。
我们从一个基于戒酒、仅限男性的住院酒精和药物康复项目中招募参与者,以研究唾液皮质醇、压力暴露、童年不良经历(ACEs)与治疗留存率之间的关系。
在项目中停留时间<90天的参与者初始皮质醇水平显著高于停留时间≥90天的参与者(0.62±0.074μg/dl对0.36±0.037μg/dl)。当我们根据参与者的皮质醇水平是低于还是高于总体平均值0.49±0.044μg/dl对参与者进行分组时,Kaplan-Meier曲线有显著差异,停药前的中位数天数分别为110天和60天。Cox比例风险模型表明,唾液皮质醇升高(以μg/dl为单位增加)、婚姻/关系状况和童年不良经历(ACEs)得分与终止项目的风险显著相关(这三个因素的风险比分别为3.49、2.39和1.50)。
皮质醇水平可能至少部分预测物质使用障碍治疗项目的留存率,无论个体有多少混杂因素或使用何种物质。如果这种方法得到验证,它可以使提供者在患者入院治疗时考虑其皮质醇水平,以促进他们坚持治疗,从而提高康复率。